Search details
1.
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
N Engl J Med
; 387(3): 217-226, 2022 07 21.
Article
in English
| MEDLINE | ID: mdl-35857659
2.
The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study.
Int J Cancer
; 154(4): 692-700, 2024 Feb 15.
Article
in English
| MEDLINE | ID: mdl-37818966
3.
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.
Lancet Oncol
; 24(8): 881-891, 2023 08.
Article
in English
| MEDLINE | ID: mdl-37451291
4.
Older adults with colon cancer are not different from younger ones, but treated differently: Retrospective analysis from single centre.
J Oncol Pharm Pract
; 28(3): 569-576, 2022 Apr.
Article
in English
| MEDLINE | ID: mdl-33752476
5.
Controlled ovarian stimulation outcomes of fertility preservation procedures in newly diagnosed breast cancer patients: a retrospective study from a single-tertiary-IVF centre.
J Obstet Gynaecol
; 42(3): 518-523, 2022 Apr.
Article
in English
| MEDLINE | ID: mdl-34382483
6.
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Lancet
; 396(10265): 1817-1828, 2020 12 05.
Article
in English
| MEDLINE | ID: mdl-33278935
7.
Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience.
Cancer Invest
; 39(6-7): 473-481, 2021.
Article
in English
| MEDLINE | ID: mdl-34014777
8.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 18(12): 1688-1700, 2017 12.
Article
in English
| MEDLINE | ID: mdl-29146401
9.
Comparison of HER2 status determination methods in HER2 (2+) patients: Manual fluorescent in situ hybridization (FISH) vs. dual silver enhanced in situ hybridization (SISH).
Ann Diagn Pathol
; 31: 36-40, 2017 Dec.
Article
in English
| MEDLINE | ID: mdl-29146056
10.
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 17(3): 367-377, 2016 Mar.
Article
in English
| MEDLINE | ID: mdl-26874901
11.
Final results of RIGHT Choice: Ribociclib plus endocrine therapy vs combination chemotherapy in premenopausal women with clinically aggressive HR+/HER2- advanced breast cancer.
J Clin Oncol
; : JCO2400144, 2024 May 21.
Article
in English
| MEDLINE | ID: mdl-38771995
12.
Assessment High-Risk Breast Cancer in Older Patients: A Comparative Analysis of PREDICT Scores and TAILORx Risk Categorization.
Eur J Breast Health
; 19(4): 325-330, 2023 Oct.
Article
in English
| MEDLINE | ID: mdl-37795003
13.
Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group.
Cancers (Basel)
; 15(6)2023 Mar 08.
Article
in English
| MEDLINE | ID: mdl-36980554
14.
Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey.
Front Oncol
; 13: 1151733, 2023.
Article
in English
| MEDLINE | ID: mdl-37448522
15.
Health-Related Quality of Life With Pembrolizumab+Chemotherapy Versus Placebo+Chemotherapy for Advanced Triple-Negative Breast Cancer: KEYNOTE-355.
J Natl Cancer Inst
; 2023 Dec 09.
Article
in English
| MEDLINE | ID: mdl-38070159
16.
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.
Eur J Cancer
; 184: 48-59, 2023 05.
Article
in English
| MEDLINE | ID: mdl-36898233
17.
Is the Effect of Tumor Localization on Prognosis Compatible with Real-life Data in Metastatic Colon Cancer? Single-Center Experience: A Retrospective Analysis.
J Gastrointest Cancer
; 53(1): 7-15, 2022 Mar.
Article
in English
| MEDLINE | ID: mdl-33665720
18.
p53 protein accumulation and presence of visceral metastasis are independent prognostic factors for survival in patients with metastatic inflammatory breast carcinoma.
Med Princ Pract
; 20(2): 159-64, 2011.
Article
in English
| MEDLINE | ID: mdl-21252573
19.
Clinical Contribution of Next-Generation Sequencing Multigene Panel Testing for BRCA Negative High-Risk Patients With Breast Cancer.
Clin Breast Cancer
; 21(6): e647-e653, 2021 12.
Article
in English
| MEDLINE | ID: mdl-33980423
20.
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
N Engl J Med
; 356(22): 2271-81, 2007 May 31.
Article
in English
| MEDLINE | ID: mdl-17538086